SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Oliva A.)
 

Search: WFRF:(Oliva A.) > The Medical Managem...

  • van Rheenen, PF (author)

The Medical Management of Paediatric Crohn's Disease: an ECCO-ESPGHAN Guideline Update

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2020-10-07
  • Oxford University Press (OUP),2021

Numbers

  • LIBRIS-ID:oai:prod.swepub.kib.ki.se:146400534
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:146400534URI
  • https://doi.org/10.1093/ecco-jcc/jjaa161DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • ObjectiveWe aimed to provide an evidence-supported update of the ECCO-ESPGHAN guideline on the medical management of paediatric Crohn’s disease [CD].MethodsWe formed 10 working groups and formulated 17 PICO-structured clinical questions [Patients, Intervention, Comparator, and Outcome]. A systematic literature search from January 1, 1991 to March 19, 2019 was conducted by a medical librarian using MEDLINE, EMBASE, and Cochrane Central databases. A shortlist of 30 provisional statements were further refined during a consensus meeting in Barcelona in October 2019 and subjected to a vote. In total 22 statements reached ≥ 80% agreement and were retained.ResultsWe established that it was key to identify patients at high risk of a complicated disease course at the earliest opportunity, to reduce bowel damage. Patients with perianal disease, stricturing or penetrating behaviour, or severe growth retardation should be considered for up-front anti-tumour necrosis factor [TNF] agents in combination with an immunomodulator. Therapeutic drug monitoring to guide treatment changes is recommended over empirically escalating anti-TNF dose or switching therapies. Patients with low-risk luminal CD should be induced with exclusive enteral nutrition [EEN], or with corticosteroids when EEN is not an option, and require immunomodulator-based maintenance therapy. Favourable outcomes rely on close monitoring of treatment response, with timely adjustments in therapy when treatment targets are not met. Serial faecal calprotectin measurements or small bowel imaging [ultrasound or magnetic resonance enterography] are more reliable markers of treatment response than clinical scores alone.ConclusionsWe present state-of-the-art guidance on the medical treatment and long-term management of children and adolescents with CD.

Added entries (persons, corporate bodies, meetings, titles ...)

  • Aloi, M (author)
  • Assa, A (author)
  • Bronsky, J (author)
  • Escher, JC (author)
  • Fagerberg, ULKarolinska Institutet (author)
  • Gasparetto, M (author)
  • Gerasimidis, K (author)
  • Griffiths, A (author)
  • Henderson, P (author)
  • Koletzko, S (author)
  • Kolho, KL (author)
  • Levine, A (author)
  • van Limbergen, J (author)
  • de Carpi, FJM (author)
  • Navas-Lopez, VM (author)
  • Oliva, S (author)
  • de Ridder, L (author)
  • Russell, RK (author)
  • Shouval, D (author)
  • Spinelli, A (author)
  • Turner, D (author)
  • Wilson, D (author)
  • Wine, E (author)
  • Ruemmele, FM (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Journal of Crohn's & colitis: Oxford University Press (OUP)15:2, s. 171-1941876-44791873-9946

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view